tiprankstipranks
Advertisement
Advertisement

ResMed CEO Farrell Exercises Options and Sells Shares Under 10b5-1 Plan

Story Highlights
  • ResMed CEO Michael Farrell exercised options and sold 4,991 shares under a pre-set Rule 10b5-1 trading plan.
  • Farrell retains a significant direct and trust-held stake in ResMed, framing the transactions as liquidity management rather than major de-risking.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
ResMed CEO Farrell Exercises Options and Sells Shares Under 10b5-1 Plan

Claim 55% Off TipRanks

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) just unveiled an announcement.

ResMed chairman and chief executive Michael J. Farrell reported a set of stock option exercises and share sales conducted under a pre-arranged Rule 10b5-1 trading plan adopted in late 2024. Farrell exercised options for 4,991 shares of ResMed common stock at an exercise price of $146.34 per share and immediately sold the same number of shares in market transactions at a weighted average price of about $251.03, leaving him with more than 466,000 shares held directly and an additional stake via the Farrell family trust.

The filing indicates that Farrell continues to hold a substantial equity position in ResMed following the transactions, suggesting the move was at least partly for personal liquidity or portfolio management rather than a full-scale reduction in exposure. Investors often monitor such insider trades for signals about management’s confidence and capital allocation, but the structured nature of the 10b5-1 plan can mitigate concerns that the timing reflects undisclosed information.

The most recent analyst rating on (AU:RMD) stock is a Hold with a A$39.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

ResMed Inc. is a U.S.-based medical device company that develops and manufactures equipment and digital solutions for the diagnosis, treatment and management of sleep apnea and other chronic respiratory disorders. The company focuses on sleep and respiratory care markets globally, providing masks, ventilators and connected software platforms for patients and healthcare providers.

Average Trading Volume: 1,111,242

Technical Sentiment Signal: Hold

Current Market Cap: A$48.13B

Find detailed analytics on RMD stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1